Somaxon's Silenor Could Switch OTC In Five To Seven Years
This article was originally published in The Pink Sheet Daily
Executive Summary
Despite a "clear path" from FDA for the insomnia drug, the firm will need to conduct efficacy, safety and label comprehension studies, and may use a lower-than-Rx dose.